Abstract:Objective:To investigate the long-term death of patients with ischemic stroke and its influencing factors.Methods:Based on the data of patients with ischemic stroke in the multi-center oral fibrinogen-lowering drug secondary prevention database, the follow-up patient information and the cause of death were registered through the epidemiological investigation method, and then compared with the baseline data of patients in the original database.Results:A total of 278 patients completed the follow-up, and 166 were in lumbrokinase group and 112 were in control group. There were 124 deaths (44.6%) within 10 years, of which 92 (74.2%) were vascular deaths. In the lumbrokinase group, 74 patients (44.6%) died of all causes and 55 (33.1%) died of vascular diseases; in the control group, 50 (44.6%) died of all causes and 37 (33.0%) died of vascular diseases. Cox proportional risk model analysis showed that lumbrokinase treatment had no significant effect on the 10-year survival rate of patients with ischemic stroke. The analysis of death influencing factors showed that the baseline international normalized ratio (INR) was significantly associated with the 10-year non-vascular death risk of patients (hazard ratio [ HR] 1.98, 95% confidence interval [ CI] 1.21-3.25; P=0.006). The greater the decrease of tissue plasminogen activator (tPA) within half a year, the lower the 10-year all-cause mortality risk ( HR 0.94, 95% CI 0.90-0.99; P=0.011); the greater the decrease in INR within one year , the lower the 10-year vascular death risk ( HR 0.41, 95% CI 0.17-0.96; P=0.040); the greater the decrease of D-dimer within one year , the higher the risk of the 10-year vascular death ( HR 1.37, 95% CI 1.02-1.83; P=0.034). The greater the decrease of INR in patients with ischemic stroke within one year, the higher the 10-year non-vascular death risk ( HR 2.15, 95% CI 1.29-3.59; P=0.004). Conclusions:The 10-year mortality rate of patients with ischemic stroke is higher, and about 3/4 are vascular deaths. The fibrinogen-lowering treatment in the acute stage has no significant effect on the 10-year all-cause mortality of patients with ischemic stroke. The greater the decrease of tPA in half a year, the lower the all-cause mortality; the greater the decrease of D-dimer level at baseline and within 1 year, the higher the 10-year vascular death; the greater the decrease of INR at baseline and within 1 year, the higher the 10-year non-vascular death risk.

A Prospective Random Double-blinded Study on the Changes of Coagulation-fibrinolysis System in Poststroke Patients Receiving Treatment of Lumbrukinase.

Changes in Coagulation and Tissue Plasminogen Activator after the Treatment of Cerebral Infarction with Lumbrokinase.

Effects of Batroxobin on Coagulation and Fibrinolytic System in the Patients with Acute Cerebral Infarction

Clinical Study the Effects of Lumbrukinase for Treatment of Acute Cerebral Infarction

Changes of plasma biomolecules in patients with acute cerebral infarction before and after treatment

Oral Fibrinogen-Depleting Agent Lumbrokinase for Secondary Ischemic Stroke Prevention: Results from a Multicenter, Randomized, Parallel-Group and Controlled Clinical Trial

Efficacy of Urinary Kallidinogenase Plus Intravenous Recombinant Tissue Plasminogen Activator for Stroke Patients With Extended Window: A Retrospective Analysis

Effects of lumbrokinase on cerebral circulation in experimental rabbit

Urokinase Combined with Liposomal Alprostadil in the Treatment of Acute Myocardial Infarction

Efficacy and Safety of Lumbrokinase Plus Aspirin Versus Aspirin Alone for Acute Ischemic Stroke (LUCENT): Study Protocol for a Multicenter Randomized Controlled Trial.

The Efficacy and Safety of Lumbrokinase Capsule in Treatment of Cerebral Infarction

A Study on the Relation of Plasma Fibrinogen and Activated Platelets in Patients with Ischemic Stroke

Laboratory investigation of fibrinolysis and platelet activation in patients with ischemic stroke by defibrase

Changes of coagulation and fibrinolysis functions following different subtypes of brain infarction

Clinical Study on the Effect of Clopidogrel Hydrogen Shlfate Tablets Combined with Batroxobin on Progressive Stroke

CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke Tenecteplase II (CHABLIS-T II): rationale and design

Dynamic Analysis for Level of Plasma TXB_2,6-keto-PGF_(1α) and TXB_2/6-keto-PGF_(1α) of Patients with Acute Cerebral Infarction and Its Clinic Significance

Comparative study of intravenous thrombolysis with rt-PA and urokinase for patients with acute cerebral infarction

Human Urinary Kallidinogenase in Treating Acute Ischemic Stroke Patients: Analyses of Pooled Data from a Randomized Double-Blind Placebo-Controlled Phase IIb and Phase III Clinical Trial

Coagulation and Fibrinolysis Parameters and Mortality in Patients with Ischemic Stroke: a 10-Year Follow-Up Study

Alterations of Hemostatic Molecular Markers During Acute Large Vessel Occlusion Stroke